Dexmedetomidine in the treatment of toxicologic conditions: a systematic review and review of the toxicology investigators consortium database

References

• Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.
   PubMed Web of Science ®Google Scholar
• Wu X-H, Cui F, Zhang C, et al. Low-dose dexmedetomidine improves sleep quality pattern in elderly patients after noncardiac surgery in the intensive care unit: a pilot randomized controlled trial. Anesthesiology. 2016;125(5):979–991.
   PubMed Web of Science ®Google Scholar
• Grape S, Kirkham KR, Frauenknecht J, et al. Intra-operative analgesia with remifentanil vs. dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(6):793–800.
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481–1501.
   PubMed Web of Science ®Google Scholar
• Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489–499.
   PubMed Web of Science ®Google Scholar
• Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–2653.
   PubMed Web of Science ®Google Scholar
• Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–1160.
   PubMed Web of Science ®Google Scholar
• Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev. 2015;1:CD010269.
   PubMedGoogle Scholar
• Zhang Z, Chen K, Ni H, et al. Sedation of mechanically ventilated adults in intensive care unit: a network meta-analysis. Sci Rep. 2017;7:44979.
   PubMed Web of Science ®Google Scholar
• Lewis K, Piticaru J, Chaudhuri D, et al. Safety and efficacy of dexmedetomidine in acutely ill adults requiring noninvasive ventilation: a systematic review and meta-analysis of randomized trials. Chest. 2021;159(6):2274–2288.
   PubMed Web of Science ®Google Scholar
• Sulton C, McCracken C, Simon HK, et al. Pediatric procedural sedation using dexmedetomidine: a report from the pediatric sedation research consortium. Hosp Pediatr. 2016;6(9):536–544.
   PubMedGoogle Scholar
• Woods AD, Giometti R, Weeks SM. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database Syst Rev Implement Rep. 2015;13:224–252.
   PubMedGoogle Scholar
• Zaidi SA, Saleem K. Safety of dexmedetomidine therapy when used as an adjunct to standard therapy for severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Chest. 2020;158(4):A614.
   Web of Science ®Google Scholar
• Fiore M, Torretta G, Passavanti MB, et al. Dexmedetomidine as adjunctive therapy for the treatment of alcohol withdrawal syndrome: a systematic review protocol. JBI Database System Rev Implement Rep. 2019;17(10):2159–2164.
   PubMedGoogle Scholar
• Peng S, Wang J, Yu H, et al. Influence of dexmedetomidine on post-operative atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2021;8:721264.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Wax PM, Kleinschmidt KC, Brent J. The toxicology investigators consortium (ToxIC) registry. J Med Toxicol. 2011;7(4):259–265.
   PubMedGoogle Scholar
• Spyres MB, Aldy K, Farrugia LA, et al. The toxicology investigators consortium 2020 annual report. J Med Toxicol. 2021;17(4):333–362.
   PubMed Web of Science ®Google Scholar
• Abdelrahman A, Borden M, Ghamloush MA. Agitated delirium in an intravenous drug user: don’t jump to conclusions [abstract]. Am J Respir Crit Care Med. 2018;197:A6929.
   Web of Science ®Google Scholar
• Achamallah N, Wright RS, Fried J. Chasing the wrong dragon: a new presentation of heroin-induced toxic leukoencephalopathy mimicking anoxic brain injury. J Intensive Care Soc. 2019;20(1):80–85.
   PubMedGoogle Scholar
• Akingbola OA, Singh D. Dexmedetomidine to treat lisdexamfetamine overdose and serotonin toxidrome in a 6-year-old girl. Am J Crit Care. 2012;21(6):456–459.
   PubMed Web of Science ®Google Scholar
• Alsukaiti W, Murray B, Carpenter J, et al. Serotonin syndrome resulting from bupropion overdose treated with cyproheptadine [abstract 025]. J Med Toxicol. 2019;15:61.
   Google Scholar
• Baddigam K, Russo P, Russo J, et al. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med. 2005;20(2):118–123.
   PubMedGoogle Scholar
• Bagdure DN, Bhoite GR, Reiter PD, et al. Dexmedetomidine in a child with methylphenidate intoxication. Indian J Pediatr. 2013;80(4):343–344.
   PubMed Web of Science ®Google Scholar
• Bassett R, Kowalski J, Boroughf W, et al. Dust-Off the ECMO, my patient just inhaled 1,1-difluoroethane [abstract 66]. Clin Toxicol. 2014;52:713.
   Web of Science ®Google Scholar
• Benzer TI, Nejad SH, Flood JG. Case records of the Massachusetts general hospital. Case 40-2013. A 36-year-old man with agitation and paranoia. N Engl J Med. 2013;369(26):2536–2545.
   PubMedGoogle Scholar
• Bernard PA, McCabe T, Bayliff S, et al. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine. J Oncol Pharm Pract. 2010;16(4):262–265.
   PubMedGoogle Scholar
• Bowcock E, Morris I, Lane A. Dexmedetomidine for acute clonidine withdrawal following intrathecal pump removal: a drug beginning to find its expanding niche. J Intensive Care Soc. 2016;17(3):271–272.
   PubMedGoogle Scholar
• Braun H, Harris M, Weinstein ZM. Management of gama-hydroxybutyrate (GHB) withdrawal in a hospitalized orthopedic patient [abstract]. J Gen Intern Med. 2019;34:S577–S578.
   Google Scholar
• Brewer A, Phillips T, Pizon A. Use of dexmedetomidine to successfully treat bupropion-induced sympathomimetic toxicity (abstract 158). Clin Toxicol. 2016;54:732.
   Web of Science ®Google Scholar
• Chiba T, Boyle K, Ganetsky M. Prolonged psychosis after 4-bromo-2,5-dimethoxyamphetamine use confirmed by GC-MS [abstract 088]. J Med Toxicol. 2019;15:80.
   Google Scholar
• Cipriani F, Mancino A, Pulitanò SM, et al. A cannabinoid-intoxicated child treated with dexmedetomidine: a case report. J Med Case Rep. 2015;9:152.
   PubMedGoogle Scholar
• Colby DK, Albertson TE, Chenoweth JA, et al. 1,4 Butanediol withdrawal and pharmacologic management: a case series [abstract 78]. Clin Toxicol. 2015;53:675.
   Web of Science ®Google Scholar
• Corcoran J, Gray T, Olives T. Prolonged serotonergic toxicity following multiple serotonergic pharmaceutical ingestion [abstract 132]. Clin Toxicol. 2019;57:942.
   Web of Science ®Google Scholar
• Cowan K, Landman RA, Saini A. Dexmedetomidine as an adjunct to treat anticholinergic toxidrome in children. Glob Pediatr Health. 2017;4:2333794X17704764.
   PubMedGoogle Scholar
• Darnell JL, Fleisch SB. Methamphetamine and wasp spray: a unique way to get a stinging high. Psychosomatics. 2019;60(5):535–536.
   PubMed Web of Science ®Google Scholar
• Defayette A, Perrello A, Brewer T, et al. Enteral baclofen withdrawal managed with intravenous dexmedetomidine: a case report. Am J Health Syst Pharm. 2020;77(5):352–355.
   PubMed Web of Science ®Google Scholar
• Dell ML, Smith W, Nemastil CJ. Dexmedetomidine use by pediatric consultation service for severe anxiety, agitation, and delirium [abstract 6.24.]. J Am Acad Child Adolesc Psychiatry. 2016;55(10):S211–S212.
   Web of Science ®Google Scholar
• Diep J, Chin DT, Gupta S, et al. Kratom, an emerging drug of abuse: a case report of overdose and management of withdrawal. A A Pract. 2018;10(8):192–194.
   PubMed Web of Science ®Google Scholar
• D’Orazi F, Mansour M. Treatment of refractory serotonin syndrome with dexmedetomidine in an adult [abstract]. Am J Respir Crit Care Med. 2014;189:A6457.
   Web of Science ®Google Scholar
• Farag E, Chahlavi A, Argalious M, et al. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg. 2006;103(6):1618–1620.
   PubMed Web of Science ®Google Scholar
• Farmer BF, Chen BC, Hoffman RS, et al. Ketamine and midazolam for procedural sedation prevents respiratory depression in life threatening aspirin toxicity [abstract 259]. Clin Toxicol. 2013;51:367–368.
   Web of Science ®Google Scholar
• Fitzgerald D, Bennett E, Mitchell M, et al. Successful physostigmine reversal of severe anticholinergic toxidrome in a child with diphenhydramine intoxication [abstract 311]. J Investig Med. 2020;68:558.
   Web of Science ®Google Scholar
• Fugate JE, White RD, Rabinstein AA. Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series. Resuscitation. 2014;85(6):774–777.
   PubMed Web of Science ®Google Scholar
• Gee SW, Lin A, Tobias JD. Dexmedetomidine infusion to control agitation due to anticholinergic toxidromes in adolescents, a case series. J Pediatr Pharmacol Ther. 2015;20(4):329–334.
   PubMedGoogle Scholar
• Ghaziuddin N, Hendriks M, Patel P, et al. Neuroleptic malignant syndrome/malignant catatonia in child psychiatry: literature review and a case series. J Child Adolesc Psychopharmacol. 2017;27(4):359–365.
   PubMed Web of Science ®Google Scholar
• Goldfine C, Lai J. Phenibut withdrawal syndrome successfully treated using oral baclofen [abstract 243]. Clin Toxicol. 2019;57:1005–1006.
   Web of Science ®Google Scholar
• Gordon B, Gugelmman H, Colby J, et al. Use of cyproheptadine to treat serotonin syndrome from coingestion of yohimbine, methylphenidate, and dextromethorphan (abstract 47). J Med Toxicol. 2015;11:20–21.
   Google Scholar
• Gottula AL, Gorder KL, Peck AR, et al. Dexmedetomidine for acute management of intrathecal baclofen withdrawal. J Emerg Med. 2019;S0736-4679(19):30827–30823.
   Google Scholar
• Hail SL, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clin Toxicol. 2013;51(3):162–166.
   PubMed Web of Science ®Google Scholar
• Hammond B, Greene E. Polymorphic ventricular tachycardia (PMVT) in an adolescent after use of synthetic cannabis: unmasked long QT syndrome [abstract 233]. J Investig Med. 2016;64:235.
   Web of Science ®Google Scholar
• Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: a comprehensive literature review and illustrative case report. Bosn J Basic Med Sci. 2019;19:125–129.
   PubMed Web of Science ®Google Scholar
• Helander A, Beck O, Bäckberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol. 2015;53(5):446–453.
   PubMed Web of Science ®Google Scholar
• Herbst J, Musgrave G. Respiratory depression following an accidental overdose of a CBD-labeled product: a pediatric case report. J Am Pharm Assoc. 2020;60(1):248–252.
   Google Scholar
• Hur MH, Havalad V, Clardy C. Strychnine: old remedy, silent killer. Pediatr Ann. 2019;48(5):e205–e207.
   PubMed Web of Science ®Google Scholar
• Ishikawa O, Barry R, Wagner I. OTC psychosis: a case of tianeptine withdrawal [abstract]. Am J Respir Crit Care Med. 2017;195:A3780.
   Web of Science ®Google Scholar
• Javed F, Benjo AM, Reddy K, et al. Dexmedetomidine use in the setting of cocaine-induced hypertensive emergency and aortic dissection: a novel indication. Case Rep Med. 2011;2011:174132.
   PubMedGoogle Scholar
• Johnson A, Chauv S, Bair JD, et al. Rapid resolution of severe lactic acidosis following hydroxocobalamin administration in an intentional potassium cyanide overdose [Abstract 132]. Clin Toxicol. 2015;53:700–701.
   Web of Science ®Google Scholar
• Jung S, Rosini JM. Dexmedetomidine for treatment of refractory heroin withdrawal. J Emerg Nurs. 2017;43(2):182–184.
   PubMed Web of Science ®Google Scholar
• Kitano T, Okajima M, Sato K, et al. Suicidal attempt with caffeine overdose treated with dexmedetomidine: a case report. J Med Case Rep. 2021;15(1):11.
   PubMedGoogle Scholar
• Knudsen K. A fatal case of consumption of beta-methylphenylamine, caffeine and dexamphetamine [abstract 70]. Clin Toxicol. 2015;53:266.
   Web of Science ®Google Scholar
• Kornas RL, Lintner CP, Taylor J, et al. Dopamine toxicity and its complications in a neonate [abstract 58]. Clin Toxicol. 2013;51:600–601.
   Web of Science ®Google Scholar
• Kunzler N, Pueringer RC, Willenbring B. Holy COWS: precipitated opioid withdrawal treated with polypharmacy including high dose fentanyl (abstract 28). Clin Toxicol. 2021;59:1050.
   Web of Science ®Google Scholar
• Lam RPK, Yip WL, Wan CK, et al. Dexmedetomidine use in the ED for control of methamphetamine-induced agitation. Am J Emerg Med. 2017;35(4):665.e1–665–e4.
   Web of Science ®Google Scholar
• Laroche J-P. Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation. BMJ Support Palliat Care. 2020;10(1):7–9.
   PubMed Web of Science ®Google Scholar
• Leikin JB, Amusina O. Use of dexmedetomidine to treat delirium primarily caused by cannabis. Am J Emerg Med. 2017;35(3):524.e1-524–e2.
   Google Scholar
• Levine M, Zorn E, O’Connor A, et al. Use of dexmedetomidine in the treatment of scorpion envenomations [abstract]. Clin Toxicol. 2009;47:763.
   Web of Science ®Google Scholar
• Linn BS, Heinrich K. Case report of adjunctive dexmedetomidine for control of methamphetamine-induced hypertension [abstract 461]. J Am Coll Clin Pharm. 2020;3:352.
   Google Scholar
• MacCamy K, Hu D. Dexmedetomidine for treatment of delayed peak symptoms of cannabis withdrawal syndrome: a case report. Hosp Pharm. 2021;56(5):462–465.
   PubMed Web of Science ®Google Scholar
• Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98(2):575–577.
   PubMed Web of Science ®Google Scholar
• MacMurdo M, Poonyagariyagorn H. A pregnant pause: the use of dexmedetomidine for agitated delirium in pregnancy [abstract 1857]. Crit Care Med. 2016;44(12):539–539.
   PubMed Web of Science ®Google Scholar
• Malakooti M, Friedman M, Smith C. Multi-organ failure associated with failure of synthetic street drug “25I” (25I-NBOME) [abstract 1127]. Crit Care Med. 2013;41:A285.
   Web of Science ®Google Scholar
• Malley C, Clark A, Westover R. Dexmedetomidine for sympathomimetic toxicity due to venlafaxine overdose (abstract 162). Clin Toxicol. 2021;59:1115.
   Web of Science ®Google Scholar
• Marino R, Scoccimarro A, Abesamis M, et al. Prolonged methylphenidate toxicity treated with continuous dexmedetomidine infusion [abstract 047]. J Med Toxicol. 2018;14:19.
   Google Scholar
• Marino R, Scoccimarro A, Pizon A. Serotonin toxicity from isolated paroxetine and hydroxyzine overdose [abstract 103]. J Med Toxicol. 2018;14:39.
   Google Scholar
• Menke N, King A, Pizon A, et al. Failure of dexmedetomidine to adequately sedate a patient with anti-muscarinic toxicity (abstract 41). J Med Toxicol. 2013;9:96.
   Google Scholar
• Mobolaji-Lawal M, Chaudhuri R, Marsh RH, et al. Generalized itching and lower-extremity spasticity in a patient with intrathecal baclofen pump. J Emerg Med. 2018;54(1):116–120.
   PubMed Web of Science ®Google Scholar
• Morr S, Heard CM, Li V, et al. Dexmedetomidine for acute baclofen withdrawal. Neurocrit Care. 2015;22(2):288–292.
   PubMed Web of Science ®Google Scholar
• Morsi RZ, Katz JA. “Zombielike” aggression in perampanel overdose. Cureus. 2021;13(5):e14971.
   PubMed Web of Science ®Google Scholar
• Murray A, Plewa MC. Case study: 26-year-old male presenting with new onset seizure and history of PTSD. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [cited 2022 Mar 16]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK500004/.
   Google Scholar
• Peterson L-K, Wiegand T. Dexmedetomidine as effective adjunctive agent in the treatment of a patient with severe alcohol and benzodiazepine withdrawal [abstract 70]. Clin Toxicol. 2011;49:543.
   Web of Science ®Google Scholar
• Ponce A, Brenner M, Ross B, et al. A tale of two botulism cases (abstract 183). Clin Toxicol. 2021;59:1125–1126.
   Web of Science ®Google Scholar
• Rahman RA, Azmi MH, Ishak NH, et al. The use of dexmedetomidine for refractory agitation in substance abuse patient. Crit Care Shock. 2010;13:18–21.
   Google Scholar
• Rajan R, Sage M. Successful emergency treatment of refractory neuroleptic malignant syndrome with electroconvulsive therapy and a novel use of dexmedetomidine: a case report from California in the era of COVID-19. J Ect. 2021;37(1):71–73.
   PubMed Web of Science ®Google Scholar
• Rushton WF, Charlton NP. Dexmedetomidine in the treatment of serotonin syndrome. Ann Pharmacother. 2014;48(12):1651–1654.
   PubMed Web of Science ®Google Scholar
• Sanders PJLT, Hanot J. Dexmedetomidine to treat 3, 4-methylenedioxymethamphetamine-induced agitation in a 13-month-old infant: a case report and literature review. J Pediatr Intensive Care. 2019;8(3):175–177.
   PubMed Web of Science ®Google Scholar
• Scarella TM, Teslyar P. Prolonged psychosis with catatonia due to 2,5-dimethoxy-4-bromoamphetamine: case report and literature review. Psychosomatics. 2019;60(6):599–602.
   PubMed Web of Science ®Google Scholar
• Schlichting E, Welter C, Schaeffer T, et al. Serotonin syndrome associated with vilazodone overdose in a 22-month-old treated with dexmedetomidine. J Emerg Med. 2021;60(2):e19–e21.
   PubMed Web of Science ®Google Scholar
• Sommer M, Grumann C, Auwarter V, et al. An ETH-LAD trip with unfavorable consequences: a case report [abstract 33]. Clin Toxicol. 2019;57:438.
   Web of Science ®Google Scholar
• Stokkeland KL, Montague AJ, Cole JB. Serotonin syndrome following high-dose dextromethorphan for the treatment of methotrexate-induced neurotoxicity (abstract 188). Clin Toxicol. 2016;54:746.
   Web of Science ®Google Scholar
• Sun C, Sweet H, Minns AB, et al. A mixed presentation of serotonin syndrome vs neuroleptic malignant syndrome in a 12-year-old boy. Pediatr Emerg Care. 2020;36:e589–e591.
   PubMed Web of Science ®Google Scholar
• Tay EM, Graham RI, Day RO. Severe GHB withdrawal delirium managed with dexmedetomidine. Med J Aust. 2016;205(6):251–252.
   PubMed Web of Science ®Google Scholar
• Thornton S, Langner T, Gerona R. Tryptamine trauma! N,N-dipropyltryptamine associated fall, seizure, and rhabdomyolysis [abstract 54. ]. J Med Toxicol. 2017;13:22.
   Google Scholar
• Tobias JD. Dexmedetomidine to control agitation and delirium from toxic ingestions in adolescents. J Pediatr Pharmacol Ther. 2010;15(1):43–48.
   PubMedGoogle Scholar
• Tran T, Estaris R, Fee C. Accidental atropine eye drop ingestion leading to anticholinergic toxidrome [abstract 118]. Oschner J. 2016;16:411.
   Google Scholar
• Vo KT, Horng H, Smollin CG, et al. Severe carisoprodol withdrawal after a 14-Year addiction and acute overdose. J Emerg Med. 2017;52(5):680–683.
   PubMed Web of Science ®Google Scholar
• Walker A, Delle Donne A, Douglas E, et al. Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome. J Med Toxicol. 2014;10(4):406–410.
   PubMedGoogle Scholar
• Ward S, Morin S, Sullivan J, et al. Dexmedetomidine in withdrawal syndromes: a case report describing dexmedetomidine in acute intrathecal baclofen pump withdrawal and review of the literature regarding alpha2-adrenergic agonist use in sedative-hypnotic withdrawal [abstract 37]. Clin Toxicol. 2009;:47:447–448.
   Web of Science ®Google Scholar
• Watt KM, Walgos J, Cheifetz IM, et al. Dexmedetomidine for transport of a spontaneously breathing combative child. Pediatrics. 2012;130(3):e690-694–e694.
   Web of Science ®Google Scholar
• White P, Faingold CL. Emergent antidepressant discontinuation syndrome misdiagnosed as delirium in the ICU. Case Rep Crit Care. 2019;2019:3925438.
   PubMedGoogle Scholar
• Wightman RS, Nelson LS, Lee JD, et al. Severe opioid withdrawal precipitated by vivitrol®. Am J Emerg Med. 2018;36(6):1128.e1-1128–e2.
   Web of Science ®Google Scholar
• Winograd E, Aaron C, Dimovska M, et al. Serotonin toxicity secondary to tianeptine overdose [abstract 093]. J Med Toxicol. 2018;14:35.
   Google Scholar
• Wolters W, Gilbert D, Hays L. Severe phenibut withdrawal: a case report and literature review [abstract 42]. Am J Addict. 2020;29:219–220.
   Web of Science ®Google Scholar
• Wu CC, McShane M, Huttlin EA, et al. Severe aggression after perampanel overdose: Case report. Psychosomatics. 2019;60(3):321–324.
   PubMed Web of Science ®Google Scholar
• Zekhtser M, Carroll E, Boyd M, et al. The role of dexmedetomidine in pediatric patients presenting with an anticholinergic toxidrome. Dinis-Oliveira RJ, editor. Case Rep Crit Care. 2021;2021:1–5.
   Google Scholar
• Calver L, Isbister GK. Dexmedetomidine in the emergency department: assessing safety and effectiveness in difficult-to-sedate acute behavioural disturbance. Emerg Med J. 2012;29(11):915–918.
   PubMed Web of Science ®Google Scholar
• Mohorn PL, Vakkalanka JP, Rushton W, et al. Evaluation of dexmedetomidine therapy for sedation in patients with toxicological events at an academic medical center. Clin Toxicol. 2014;52(5):525–530.
   Web of Science ®Google Scholar
• Rizer J, Oldham R, Rege S, et al. Dexmedetomidine use in the critically ill poisoned patient [abstract 067]. J Med Toxicol. 2018;14:26.
   Google Scholar
• Nasr DAM, Omran HASA, Hakim SM, et al. Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia. J Opioid Manag. 2011;7(5):337–344.
   PubMedGoogle Scholar
• Kershner E, Tobarran N, Rose R, et al. Clinical characteristics and outcomes using dexmedetomidine in non-intubated patients, a poison center observational study (abstract 225). Clin Toxicol. 2021;59:1145–1146.
   Web of Science ®Google Scholar
• Laube C, Heise C, Kang P. Retrospective study of dexmedetomidine for anticholinergic delirium (abstract 233). Clin Toxicol. 2021;59:1149.
   Web of Science ®Google Scholar
• Adams C, Schult R, Acquisto N, et al. Bupropion exposures: seizures and severe toxicity [abstract 193]. Clin Toxicol. 2014;52:769–770.
   Web of Science ®Google Scholar
• Kamijo Y, Takai M, Fujita Y, et al. A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan. Am J Drug Alcohol Abuse. 2016;42(5):513–519.
   PubMed Web of Science ®Google Scholar
• Murphy CM, Dulaney AR, Beuhler MC, et al. “Bath salts” and “plant food” products: the experience of one regional US poison center. J Med Toxicol. 2013;9(1):42–48.
   PubMedGoogle Scholar
• Rushton W, Whitworth B, Brown J, et al. Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol (Phila). 2021;59(2):152–157.
   PubMed Web of Science ®Google Scholar
• Thornton S, Whitacre J, Pallo N, et al. In search of acute benzodiazepine withdrawal: a retrospective review of an academic medical center’s experience [abstract 065]. J Med Toxicol. 2018;14:25–26.
   Google Scholar
• Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila). 2022;60(2):143–158.
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–713.
   PubMed Web of Science ®Google Scholar
• Dunkley EJC, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
   PubMed Web of Science ®Google Scholar
• Wang S, Hong Y, Li S, et al. Effect of dexmedetomidine on delirium during sedation in adult patients in intensive care units: a systematic review and meta-analysis. J Clin Anesth. 2021;69:110157.
   PubMed Web of Science ®Google Scholar
• Boley SP, Olives TD, Bangh SA, et al. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. Clin Toxicol. 2019;57(1):50–55.
   PubMed Web of Science ®Google Scholar
• Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol. 2018;56(2):101–107.
   PubMed Web of Science ®Google Scholar
• Kontak AC, Victor RG, Vongpatanasin W. Dexmedetomidine as a novel countermeasure for cocaine-induced central sympathoexcitation in cocaine-addicted humans. Hypertension. 2013;61(2):388–394.
   PubMed Web of Science ®Google Scholar
• Menon DV, Wang Z, Fadel PJ, et al. Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol. 2007;50(7):626–633.
   PubMed Web of Science ®Google Scholar
• Whittington RA, Virag L, Vulliemoz Y, et al. Dexmedetomidine increases the cocaine seizure threshold in rats. Anesthesiology. 2002;97(3):693–700.
   PubMed Web of Science ®Google Scholar
• Seyit M, Erdur B, Kortunay S, et al. A comparison of dexmedetomidine, moxonidine and alpha-methyldopa effects on acute, lethal cocaine toxicity. Iran Red Crescent Med J. 2015;17(6):e18780.
   PubMed Web of Science ®Google Scholar
• Kersten JR, Pagel PS, Hettrick DA, et al. Dexmedetomidine partially attenuates the sympathetically mediated systemic and coronary hemodynamic effects of cocaine. Anesth Analg. 1995;80(1):114–121.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Lejeune F, Gobert A, et al. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000;295(3):1206–1222.
   PubMed Web of Science ®Google Scholar
• Rabin BC, Guo TZ, Gregg K, et al. Role of serotonergic neurotransmission in the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1996;306(1-3):51–59.
   PubMed Web of Science ®Google Scholar
• Gobert A, Rivet JM, Audinot V, et al. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience. 1998;84(2):413–429.
   PubMed Web of Science ®Google Scholar
• Hopwood SE, Stamford JA. Noradrenergic modulation of serotonin release in rat dorsal and median raphé nuclei via alpha(1) and alpha(2A) adrenoceptors. Neuropharmacology. 2001;41(4):433–442.
   PubMed Web of Science ®Google Scholar
• Kawano T, Takahashi T, Kaminaga S, et al. A comparison of midazolam and dexmedetomidine for the recovery of serotonin syndrome in rats. J Anesth. 2015;29(4):631–634.
   PubMed Web of Science ®Google Scholar
• Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615–619.
   PubMedGoogle Scholar
• Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–109.
   PubMed Web of Science ®Google Scholar
• Gussow L. Toxicology rounds: no evidence supports using cyproheptadine for treating serotonin syndrome. Emerg Med News. 2020;42(10):18–18.
   Google Scholar
• Mullins ME. Letter to the editor: Evidence supports cyproheptadine. Emerg Med News. 2021;43:6.
   Google Scholar
• Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
   PubMed Web of Science ®Google Scholar